Lucid Diagnostics Inc. LUCD
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a GI/hepatology diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EsoGuard (LDT, CLIA/CAP lab; EsoGuard 2.0 multiplexed assay) | Barrett's esophagus / esophageal adenocarcinoma precancer detection | — | NA_NON_THERAPEUTIC |
| EsoCheck (FDA 510(k)-cleared, CE marked) | Esophageal surface cell collection | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other GI/hepatology companies
- PAVmed Inc. PAVM
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.